ALPMY News and Press, Astellas Pharma Inc. ADR From 07/16/18

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Array's melanoma combo gets a guideline nod Company: Array Biopharma ( ARRY ) Therapy:...

TOKYO and NEW YORK , July 13, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") and Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) fo...

Quick Take Constellation Pharmaceuticals ( CNST ) intends to raise gross proceeds of $80 million from a U.S. IPO, according to an S-1/A registration statement . The firm is a clinical-stage biopharmaceutical company which uses epigenetics, a regulatory system that controls gene expres...

Bloomberg reports that, despite the recent concession from Pfizer to delay its price hikes until year-end, some drug makers are ignoring the political climate and instituting price increases now. Recent examples: More news on: Celgene Corporation, Novo Nordisk A/S, Intercept Pharmaceutic...

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Acceleron and Celgene land another big blow with their TGF blocker Company: Acceleron...

The most important weapon we as investors have in our arsenals is knowledge. Many of the people I've spoken with on Seeking Alpha and other forums have demonstrated keen awareness of the clinical pipeline for their company of interest. However, it is often difficult for them to place the resul...

BOTHELL, Wash. , and TOKYO , July 9, 2018 /PRNewswire/ --  Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") today announced completion of enrollment for the enfortumab vedotin EV-201 pivotal phase ...

Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Acceleron reaches for the gold in a pivotal trial Company: Acceleron ( XLRN ) and Celgene ( CELG ) Therapy: Lusp...

TOKYO , June 29, 2018 /PRNewswire/ -- Results show enzalutamide plus androgen deprivation therapy significantly reduced the risk of developing metastases or death by 71 percent compared to placebo plus androgen deprivation therapy [i] FOR EMEA MEDICAL MEDIA ONLY - Astellas Pharma...

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. The world of biotech investing revolves first and foremost around the regulatory agencies like th...